Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease

International Review of Neurobiology

Volumn 132, Issue , 2017, Pages 275-294

  Johar, Iskandar ^a   Mollenhauer, Brit ^b,c   Aarsland, Dag ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Paracelsus Elena Clinic   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Biomarkers; Cerebrospinal fluid; Cognitive impairment; Dementia; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

CEREBROSPINAL FLUID; COGNITIVE DEFECT; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; EXECUTIVE FUNCTION; HUMAN; LUMBAR PUNCTURE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; OLIGOMERIZATION; PARKINSON DISEASE; POSTDURAL PUNCTURE HEADACHE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; COMPLICATION;

BIOMARKERS; COGNITIVE DYSFUNCTION; HUMANS; PARKINSON DISEASE;

EID: 85011807527     PISSN: 00747742     EISSN: 21625514     Source Type: Book Series    
DOI: 10.1016/bs.irn.2016.12.001     Document Type: Chapter

References (73)

1. Aarsland, D., Bronnick, K., Larsen, J.P., Tysnes, O.B., Alves, G., Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest study. Neurology 72:13 (2009), 1121–1126, 10.1212/01.wnl.0000338632.00552.cb.
2. Aarsland, D., Zaccai, J., Brayne, C., A systematic review of prevalence studies of dementia in Parkinson's disease. Movement Disorders 20:10 (2005), 1255–1263, 10.1002/mds.20527.
3. Abdelnour, C., van Steenoven, I., Londos, E., Blanc, F., Auestad, B., Kramberger, M.G., Aarsland, D., Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia. Movement Disorders 31:8 (2016), 1203–1208, 10.1002/mds.26668.
4. Alves, G., Bronnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., Mulugeta, E., CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: The Norwegian ParkWest study. Journal of Neurology, Neurosurgery, and Psychiatry 81:10 (2010), 1080–1086, 10.1136/jnnp.2009.199950.
5. Alves, G., Lange, J., Blennow, K., Zetterberg, H., Andreasson, U., Forland, M.G., Pedersen, K.F., CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology 82:20 (2014), 1784–1790, 10.1212/wnl.0000000000000425.
6. Armon, C., Evans, R.W., Addendum to assessment: Prevention of post-lumbar puncture headaches: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 65:4 (2005), 510–512, 10.1212/01.wnl.0000173034.96211.1b.
7. Bachhuber, T., Katzmarski, N., McCarter, J.F., Loreth, D., Tahirovic, S., Kamp, F., Meyer-Luehmann, M., Inhibition of amyloid-beta plaque formation by alpha-synuclein. Nature Medicine 21:7 (2015), 802–807, 10.1038/nm.3885.
8. Backstrom, D.C., Eriksson Domellof, M., Linder, J., Olsson, B., Ohrfelt, A., Trupp, M., Forsgren, L., Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurology 72:10 (2015), 1175–1182, 10.1001/jamaneurol.2015.1449.
9. Bereczki, E., Francis, P.T., Howlett, D., Pereira, J.B., Hoglund, K., Bogstedt, A., Aarsland, D., Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. Alzheimer's & Dementia 12:11 (2016), 1149–1158, 10.1016/j.jalz.2016.04.005.
10. Beyer, M.K., Alves, G., Hwang, K.S., Babakchanian, S., Bronnick, K.S., Chou, Y.Y., Apostolova, L.G., Cerebrospinal fluid Abeta levels correlate with structural brain changes in Parkinson's disease. Movement Disorders 28:3 (2013), 302–310, 10.1002/mds.25282.
11. Blennow, K., Wallin, A., Hager, O., Low frequency of post-lumbar puncture headache in demented patients. Acta Neurologica Scandinavica 88:3 (1993), 221–223.
12. Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 24:2 (2003), 197–211.
13. Buddhala, C., Campbell, M.C., Perlmutter, J.S., Kotzbauer, P.T., Correlation between decreased CSF alpha-synuclein and Abeta(1)(-)(4)(2) in Parkinson disease. Neurobiology of Aging 36:1 (2015), 476–484, 10.1016/j.neurobiolaging.2014.07.043.
14. Caviness, J.N., Driver-Dunckley, E., Connor, D.J., Sabbagh, M.N., Hentz, J.G., Noble, B., Adler, C.H., Defining mild cognitive impairment in Parkinson's disease. Movement Disorders 22:9 (2007), 1272–1277, 10.1002/mds.21453.
15. Chiasserini, D., Parnetti, L., Andreasson, U., Zetterberg, H., Giannandrea, D., Calabresi, P., Blennow, K., CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. Journal of Alzheimer's Disease 22:4 (2010), 1281–1288, 10.3233/jad-2010-101293.
16. Compta, Y., Marti, M.J., Ibarretxe-Bilbao, N., Junque, C., Valldeoriola, F., Munoz, E., Tolosa, E., Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Movement Disorders 24:15 (2009), 2203–2210, 10.1002/mds.22594.
17. Compta, Y., Parkkinen, L., O'Sullivan, S.S., Vandrovcova, J., Holton, J.L., Collins, C., Revesz, T., Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: Which is more important?. Brain 134:Pt. 5 (2011), 1493–1505, 10.1093/brain/awr031.
18. Compta, Y., Pereira, J.B., Rios, J., Ibarretxe-Bilbao, N., Junque, C., Bargallo, N., Marti, M.J., Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study. Parkinsonism & Related Disorders 19:8 (2013), 717–724, 10.1016/j.parkreldis.2013.03.009.
19. Compta, Y., Valente, T., Saura, J., Segura, B., Iranzo, A., Serradell, M., Marti, M.J., Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson's disease. Journal of Neurology 262:2 (2015), 294–306, 10.1007/s00415-014-7560-z.
20. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E., Lansbury, P.T. Jr., Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences of the United States of America 97:2 (2000), 571–576.
21. Delgado-Alvarado, M., Gago, B., Navalpotro-Gomez, I., Jimenez-Urbieta, H., Rodriguez-Oroz, M.C., Biomarkers for dementia and mild cognitive impairment in Parkinson's disease. Movement Disorders 31:6 (2016), 861–881, 10.1002/mds.26662.
22. Duits, F.H., Martinez-Lage, P., Paquet, C., Engelborghs, S., Lleo, A., Hausner, L., Blennow, K., Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's & Dementia 12:2 (2016), 154–163, 10.1016/j.jalz.2015.08.003.
23. El-Agnaf, O.M., Walsh, D.M., Allsop, D., Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurology 2:8 (2003), 461–462.
24. Fullard, M.E., Tran, B., Xie, S.X., Toledo, J.B., Scordia, C., Linder, C., Morley, J.F., Olfactory impairment predicts cognitive decline in early Parkinson's disease. Parkinsonism & Related Disorders 25 (2016), 45–51, 10.1016/j.parkreldis.2016.02.013.
25. Gao, L., Tang, H., Nie, K., Wang, L., Zhao, J., Gan, R., Wang, L., Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: A systematic review and meta-analysis. The International Journal of Neuroscience 125:9 (2015), 645–654, 10.3109/00207454.2014.961454.
26. Guillaume, E., Zimmermann, C., Burkhard, P.R., Hochstrasser, D.F., Sanchez, J.C., A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 3:8 (2003), 1495–1499, 10.1002/pmic.200300478.
27. Hall, S., Ohrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Hansson, O., Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Archives of Neurology 69:11 (2012), 1445–1452, 10.1001/archneurol.2012.1654.
28. Hall, S., Surova, Y., Ohrfelt, A., Blennow, K., Zetterberg, H., Hansson, O., Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson's disease. Movement Disorders 31:6 (2016), 898–905, 10.1002/mds.26578.
29. Hall, S., Surova, Y., Ohrfelt, A., Zetterberg, H., Lindqvist, D., Hansson, O., CSF biomarkers and clinical progression of Parkinson disease. Neurology 84:1 (2015), 57–63, 10.1212/wnl.0000000000001098.
30. Hammond, E.R., Wang, Z., Bhulani, N., McArthur, J.C., Levy, M., Needle type and the risk of post-lumbar puncture headache in the outpatient neurology clinic. Journal of the Neurological Sciences 306:1–2 (2011), 24–28, 10.1016/j.jns.2011.04.004.
31. Hansson, O., Hall, S., Ohrfelt, A., Zetterberg, H., Blennow, K., Minthon, L., El-Agnaf, O.M., Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's Research & Therapy, 6(3), 2014, 25, 10.1186/alzrt255.
32. Hirsch, E.C., Vyas, S., Hunot, S., Neuroinflammation in Parkinson's disease. Parkinsonism & Related Disorders 18:Suppl. 1 (2012), S210–S212, 10.1016/s1353-8020(11)70065-7.
33. Irwin, D.J., Lee, V.M., Trojanowski, J.Q., Parkinson's disease dementia: Convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nature Reviews. Neuroscience 14:9 (2013), 626–636, 10.1038/nrn3549.
34. Jellinger, K.A., Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathologica 120:6 (2010), 829–830, 10.1007/s00401-010-0755-1 author reply 831.
35. Kang, J.H., Irwin, D.J., Chen-Plotkin, A.S., Siderowf, A., Caspell, C., Coffey, C.S., Shaw, L.M., Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurology 70:10 (2013), 1277–1287, 10.1001/jamaneurol.2013.3861.
36. Leverenz, J.B., Watson, G.S., Shofer, J., Zabetian, C.P., Zhang, J., Montine, T.J., Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism & Related Disorders 17:1 (2011), 61–64, 10.1016/j.parkreldis.2010.10.003.
37. Lindqvist, D., Hall, S., Surova, Y., Nielsen, H.M., Janelidze, S., Brundin, L., Hansson, O., Cerebrospinal fluid inflammatory markers in Parkinson's disease—Associations with depression, fatigue, and cognitive impairment. Brain, Behavior, and Immunity 33 (2013), 183–189, 10.1016/j.bbi.2013.07.007.
38. Litvan, I., Goldman, J.G., Troster, A.I., Schmand, B.A., Weintraub, D., Petersen, R.C., Emre, M., Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement Disorders 27:3 (2012), 349–356, 10.1002/mds.24893.
39. Liu, C., Cholerton, B., Shi, M., Ginghina, C., Cain, K.C., Auinger, P., Zhang, J., CSF tau and tau/Abeta42 predict cognitive decline in Parkinson's disease. Parkinsonism & Related Disorders 21:3 (2015), 271–276, 10.1016/j.parkreldis.2014.12.027.
40. Maetzler, W., Schmid, B., Synofzik, M., Schulte, C., Riester, K., Huber, H., Melms, A., The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. Journal of Alzheimer's Disease 19:3 (2010), 937–942, 10.3233/jad-2010-1289.
41. Maetzler, W., Stapf, A.K., Schulte, C., Hauser, A.K., Lerche, S., Wurster, I., Berg, D., Serum and cerebrospinal fluid uric acid levels in Lewy body disorders: Associations with disease occurrence and amyloid-beta pathway. Journal of Alzheimer's Disease 27:1 (2011), 119–126, 10.3233/jad-2011-110587.
42. Mathews, P.M., Levy, E., Cystatin C in aging and in Alzheimer's disease. Ageing Research Reviews 32 (2016), 38–50, 10.1016/j.arr.2016.06.003.
43. McGeer, P.L., McGeer, E.G., Inflammation and the degenerative diseases of aging. The Annals of the New York Academy of Sciences 1035 (2004), 104–116, 10.1196/annals.1332.007.
44. Mollenhauer, B., Parnetti, L., Rektorova, I., Kramberger, M.G., Pikkarainen, M., Schulz-Schaeffer, W.J., Schlossmacher, M.G., Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Journal of Neurochemistry 139 (2015), 290–317, 10.1111/jnc.13390.
45. Mollenhauer, B., Trenkwalder, C., von Ahsen, N., Bibl, M., Steinacker, P., Brechlin, P., Otto, M., Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dementia and Geriatric Cognitive Disorders 22:3 (2006), 200–208, 10.1159/000094871.
46. Montine, T.J., Shi, M., Quinn, J.F., Peskind, E.R., Craft, S., Ginghina, C., Zhang, J., CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Movement Disorders 25:15 (2010), 2682–2685, 10.1002/mds.23287.
47. Ohrfelt, A., Zetterberg, H., Andersson, K., Persson, R., Secic, D., Brinkmalm, G., Westman-Brinkmalm, A., Identification of novel alpha-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. Neurochemical Research 36:11 (2011), 2029–2042, 10.1007/s11064-011-0527-x.
48. Olsson, B., Lautner, R., Andreasson, U., Ohrfelt, A., Portelius, E., Bjerke, M., Zetterberg, H., CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis. Lancet Neurology 15:7 (2016), 673–684, 10.1016/s1474-4422(16)00070-3.
49. Otto, M., Esselmann, H., Schulz-Shaeffer, W., Neumann, M., Schroter, A., Ratzka, P., Wiltfang, J., Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54:5 (2000), 1099–1102.
50. Park, M.J., Cheon, S.M., Bae, H.R., Kim, S.H., Kim, J.W., Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. Journal of Clinical Neurology 7:4 (2011), 215–222, 10.3988/jcn.2011.7.4.215.
51. Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., De Carlo, C., Giannandrea, D., Calabresi, P., Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's disease. Frontiers in Aging Neuroscience, 6, 2014, 53, 10.3389/fnagi.2014.00053.
52. Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D'Amore, C., Calabresi, P., Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biological Psychiatry 64:10 (2008), 850–855, 10.1016/j.biopsych.2008.02.016.
53. Peskind, E., Nordberg, A., Darreh-Shori, T., Soininen, H., Safety of lumbar puncture procedures in patients with Alzheimer's disease. Current Alzheimer Research 6:3 (2009), 290–292.
54. Peskind, E.R., Riekse, R., Quinn, J.F., Kaye, J., Clark, C.M., Farlow, M.R., Galasko, D., Safety and acceptability of the research lumbar puncture. Alzheimer Disease and Associated Disorders 19:4 (2005), 220–225.
55. Pienaar, I.S., Burn, D., Morris, C., Dexter, D., Synaptic protein alterations in Parkinson's disease. Molecular Neurobiology 45:1 (2012), 126–143, 10.1007/s12035-011-8226-9.
56. Reiber, H., Proteins in cerebrospinal fluid and blood: Barriers, CSF flow rate and source-related dynamics. Restorative Neurology and Neuroscience 21:3–4 (2003), 79–96.
57. Schmid, A.W., Fauvet, B., Moniatte, M., Lashuel, H.A., Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Molecular & Cellular Proteomics 12:12 (2013), 3543–3558, 10.1074/mcp.R113.032730.
58. Schrag, A., Jahanshahi, M., Quinn, N., What contributes to quality of life in patients with Parkinson's disease?. Journal of Neurology, Neurosurgery, and Psychiatry 69:3 (2000), 308–312.
59. Schulz-Schaeffer, W.J., The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathologica 120:2 (2010), 131–143, 10.1007/s00401-010-0711-0.
60. Siderowf, A., Xie, S.X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., Clark, C., CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 75:12 (2010), 1055–1061, 10.1212/WNL.0b013e3181f39a78.
61. Simonsen, A.H., Kuiperij, B., El-Agnaf, O.M., Engelborghs, S., Herukka, S.K., Parnetti, L., Mollenhauer, B., The utility of alpha-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature. Biomarkers in Medicine 10:1 (2016), 19–34, 10.2217/bmm.14.105.
62. Skogseth, R.E., Bronnick, K., Pereira, J.B., Mollenhauer, B., Weintraub, D., Fladby, T., Aarsland, D., Associations between cerebrospinal fluid biomarkers and cognition in early untreated Parkinson's disease. Journal of Parkinson's Disease 5:4 (2015), 783–792, 10.3233/jpd-150682.
63. Stav, A.L., Aarsland, D., Johansen, K.K., Hessen, E., Auning, E., Fladby, T., Amyloid-beta and alpha-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Parkinsonism & Related Disorders 21:7 (2015), 758–764, 10.1016/j.parkreldis.2015.04.027.
64. Stewart, T., Liu, C., Ginghina, C., Cain, K.C., Auinger, P., Cholerton, B., Zhang, J., Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. The American Journal of Pathology 184:4 (2014), 966–975, 10.1016/j.ajpath.2013.12.007.
65. Terrelonge, M. Jr., Marder, K.S., Weintraub, D., Alcalay, R.N., CSF beta-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. Journal of Molecular Neuroscience 58:1 (2016), 88–92, 10.1007/s12031-015-0647-x.
66. Tokuda, T., Qureshi, M.M., Ardah, M.T., Varghese, S., Shehab, S.A., Kasai, T., El-Agnaf, O.M., Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75:20 (2010), 1766–1772, 10.1212/WNL.0b013e3181fd613b.
67. van de Beek, D., Drake, J.M., Tunkel, A.R., Nosocomial bacterial meningitis. New England Journal of Medicine 362 (2010), 146–154 http://dx.doi/10.1056/NEJMra0804573.
68. Vidoni, E.D., Morris, J.K., Raider, K., Burns, J.M., Reducing post-lumbar puncture headaches with small bore atraumatic needles. Journal of Clinical Neuroscience 21:3 (2014), 536–537, 10.1016/j.jocn.2013.07.001.
69. Vranova, H.P., Henykova, E., Kaiserova, M., Mensikova, K., Vastik, M., Mares, J., Kanovsky, P., Tau protein, beta-amyloid(1)(-)(4)(2) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. Journal of the Neurological Sciences 343:1–2 (2014), 120–124, 10.1016/j.jns.2014.05.052.
70. Whitfield, D.R., Vallortigara, J., Alghamdi, A., Howlett, D., Hortobagyi, T., Johnson, M., Francis, P.T., Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: Association with cognitive impairment. Neurobiology of Aging 35:12 (2014), 2836–2844, 10.1016/j.neurobiolaging.2014.06.015.
71. Yarnall, A.J., Breen, D.P., Duncan, G.W., Khoo, T.K., Coleman, S.Y., Firbank, M.J., Burn, D.J., Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD study. Neurology 82:4 (2014), 308–316, 10.1212/wnl.0000000000000066.
72. Yu, S.Y., Zuo, L.J., Wang, F., Chen, Z.J., Hu, Y., Wang, Y.J., Zhang, W., Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: A cross-sectional study. BMC Neurology, 14, 2014, 113, 10.1186/1471-2377-14-113.
73. Zetterberg, H., Tullhog, K., Hansson, O., Minthon, L., Londos, E., Blennow, K., Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. European Neurology 63:6 (2010), 326–330, 10.1159/000311703.